April 14, 2018 Atomic Spectroscopy PR/Corporate

Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting

Basel, 14 April 2018 Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting Data highlight commitment to personalised cancer immunotherapy combinations that stimulate deep anti-cancer immune responses Updated data from the Phase III IMpower150 study shows clinically meaningful... Read more

April 6, 2018 M&A, Partnerships

Roche completes acquisition of Flatiron Health

Basel, 06 April 2018 Roche completes acquisition of Flatiron Health Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as... Read more

April 6, 2018 M&A, Partnerships

Roche completes acquisition of Flatiron Health

Basel, 06 April 2018 Roche completes acquisition of Flatiron Health Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as... Read more

April 6, 2018 M&A, Partnerships

Roche completes acquisition of Flatiron Health

Basel, 06 April 2018 Roche completes acquisition of Flatiron Health Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as... Read more

March 26, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Basel, 26 March 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel These additional data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines... Read more

March 26, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Basel, 26 March 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel These additional data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines... Read more

March 22, 2018 Acad, Gov/Utilities

FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy

Basel, 22 March 2018 FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy First and only prefilled syringe treatment option FDA-approved to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME) Diabetic retinopathy is the leading cause of blindness among adults aged... Read more

March 20, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Basel, 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its... Read more